FDA Grants RMAT Status to Hope Biosciences for MS Treatment

The US Food and Drug Administration (FDA) has designated the adipose-derived mesenchymal stem cells (HB-adMSCs) developed by Hope Biosciences as a regenerative medicine advanced therapy (RMAT). This important designation aims to facilitate the treatment of individuals diagnosed with relapsing-remitting multiple sclerosis (RRMS). The decision was based on promising results from a Phase II clinical trial conducted by the Hope Biosciences Research Foundation (HBRF), a non-profit clinical research organization based in the United States.

This trial, which took place from 2023 to 2024, represents a significant milestone as it was the first instance globally where patients with multiple sclerosis received multiple high doses of pure mesenchymal stem cells. In the randomised, double-blind trial, 24 subjects participated and received a total of six intravenous infusions. Each infusion contained 200 million stem cells, amounting to a total of 1.2 billion cells administered over a 32-week period.

The HB-adMSCs have been explored in over 50 clinical studies and expanded access programs, authorised by the FDA, for various medical conditions. Participants in these studies have included individuals aged from 18 months to over 90 years. The treatments have been provided under the Federal Right to Try Act for patients with serious or life-threatening conditions.

To qualify for RMAT status, therapies must demonstrate preliminary clinical evidence indicating their potential to address serious conditions with unmet medical needs. Donna Chang, CEO of Hope Biosciences, expressed enthusiasm regarding the RMAT designation, stating, “Receiving the first RMAT designation for multiple sclerosis is a tremendous acknowledgment of our technology’s potential to impact the world of debilitating autoimmune conditions.” Chang highlighted the collaborative effort with HBRF, praising their expertise in cell therapy and commitment to patient-centered care.

The RMAT designation is critical as it can expedite the development and review process for therapies that show promise in treating serious conditions. As Hope Biosciences continues its work, the significance of this designation underscores the potential for innovative treatments in the field of regenerative medicine.

This advancement not only represents a leap forward in the treatment of RRMS but also reflects the ongoing commitment of researchers and developers to address unmet medical needs effectively. The collaboration between Hope Biosciences and HBRF may pave the way for future breakthroughs in the treatment of other debilitating conditions.